Cymabay Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

CymaBay Therapeutics

17/03/2022 22:14

* Cymabay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted
loss of 34 cents​​ per share for the quarter ended in December.
The mean expectation of nine analysts for the quarter was for a
loss of 26 cents per share.
    * Reported revenue was zero​;  analysts expected $6.43
million. 
    * Cymabay Therapeutics Inc's reported EPS for the quarter
was a
loss of 34 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cymabay Therapeutics Inc shares had fallen by 9.8% this
quarter.
    * The company reported a quarterly loss of $26.54 million.
    * Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $11.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated March 17 at 10:14 p.m.  ​All
figures in US dollars unless otherwise stated